NASDAQ · Biotechnology

MIRM (MIRM) Stock

$107.57 -4.15% NASDAQ: MIRM Healthcare

Valuation

MetricValue
Price$107.57
Market Cap$6.56B
P/E Ratio-191.54
P/B Ratio26.85
P/S Ratio9.01
EPS (TTM)$-13.60
52-Week High$128.95
52-Week Low$42.89
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-3.36%
ROA-5.94%
ROCE-7.03%
Gross Margin81.39%
Operating Margin-39.51%
Net Margin-1.40%
Debt/Equity1.34
Current Ratio2.09

Annual Financials (USD)

Metric20212022202320242025
Revenue$19.0M$77.0M$186.0M$337.0M$521.0M
Operating Profit$-173.0M$-131.0M$-109.0M$-88.0M$-22.0M
Net Profit$-84.0M$-136.0M$-163.0M$-88.0M$-23.0M
EPS$-2.77$-4.02$-4.00$-1.85$-0.47
Op Margin-906.1%-170.3%-58.6%-26.0%-4.3%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$295.0M$353.0M$647.0M$671.0M$843.0M
Total Liabilities$174.0M$211.0M$398.0M$445.0M$528.0M
Cash$31.0M$28.0M$286.0M$223.0M$297.0M
Borrowings$3.0M$2.0M$308.0M$318.0M$319.0M

Latest News

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire · Jul 13, 2026 Mirum Pharmaceuticals Insider Sold Shares Worth $2,445,382, According to a Recent SEC Filing MT Newswires · Jul 8, 2026 Mirum Pharmaceuticals Insider Sold Shares Worth $611,273, According to a Recent SEC Filing MT Newswires · Jul 8, 2026 Stocks To Watch: 14 Names Test And Tease New Buy Zones Investor's Business Daily · Jul 8, 2026 RBC Capital Adjusts Mirum Pharmaceuticals Price Target to $148 From $142, Maintains Outperform Rating MT Newswires · Jul 7, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-133.0M$-120.0M$-71.0M$10.0M$56.0M
Investing Cash Flow$30.0M$7.0M$-127.0M$-91.0M$-25.0M
Financing Cash Flow$67.0M$2.0M$-185.0M$0$0
Net Cash Flow$-11.0M$-3.0M$158.0M$-63.0M$75.0M
Free Cash Flow$-152.0M$-120.0M$-91.0M$9.0M$55.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.01
EV / EBITDA-128.97
FCF Yield-3.22%
Quick Ratio1.99
Interest Coverage-1.57
Return 1Y125.31%
Return 3Y352.11%
Return 5Y643.17%

Ownership

Insiders Held1.39%
Institutions Held114.40%
Institutions Float Held116.01%
Institutional HolderSharesReport Date
Frazier Life Sciences Management, L.P. 7,679,6842026-03-31
Janus Henderson Group PLC6,945,8132026-03-31
Blackrock Inc.3,846,5302026-03-31
Vanguard Capital Management LLC2,414,7762026-03-31
FMR, LLC1,965,3752026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ACAD $29.21 +2.67% 8.94 $5.00B 0.00%
ADMA $8.71 -0.91% 12.17 $2.02B 0.00%
BLTEBelite Bio, Inc $157.14 -2.45% -61.62 $6.30B 0.00%
DYN $25.97 +2.89% -6.05 $4.85B 0.00%
LGND $293.15 -2.33% 28.98 $5.88B 0.00%

About MIRM

MIRM is led by CEO Christopher Peetz, employs 418 people, headquartered in Foster City, US, publicly traded since 2019.

MIRM stock trades at $107.57 with a market capitalization of $6.56B. The stock is valued at a price-to-earnings (P/E) ratio of -191.54, price-to-book of 26.85, price-to-sales of 9.01. Over the past 52 weeks the stock has ranged between $42.89 and $128.95, and currently trades 16.6% below its 52-week high.

On profitability, MIRM generates a return on equity (ROE) of -3.36%, return on capital employed of -7.03%, an operating margin of -39.51%, a net profit margin of -1.40%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides